Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epicorticosterone SCHEMBL19465689 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Corticosterone SCHEMBL22612 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL14592717 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL17287012 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL4380327 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL20058459 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL9070639 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL15920519 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL21168995 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG | |
| Epicorticosterone SCHEMBL20242898 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ANR3C2LMNASHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426285-B1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CARTESIAN THERAPEUTICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20230119226-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230107561-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-3980784-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | Selecta Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210187081-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20200399628-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020247625-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (GB) | 2020-12-10 | — | — | WO | disclosed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180289776-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTIINFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20170258927-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-1729570-A1 | ION CHANNEL | Paradigm Therapeutics Ltd. (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094569-A1 | ION CHANNEL | PARADIGM THERAPEUTICS LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | PPP3R1, CHP1, NR3C1 | SMN1; SMN2 4855/4885HIF1A 4422/4885NR3C2 16/4885 |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | HAVCR2, CCL5, IRF3 | SMN1; SMN2 2407/4885HIF1A 3484/4885NR3C2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.